Table 1.
Geographic and clinical characteristics of the 195 patients enrolled in the study
| Total (n = 195) |
Controlled (n = 119) |
Uncontrolled (n = 76) |
P-value | |
|---|---|---|---|---|
| Age (years) (range) |
55 (10 ~ 87) |
57 (10 ~ 87) |
51 (20 ~ 81) |
0.233 |
| Male (%) |
101 (51.8%) |
64 (53.8%) |
37 (48.7%) |
0.557 |
| Comorbidity (%) |
61 (31.3%) |
31 (26.1%) |
30 (39.5%) |
0.058 |
|
Diagnostic time (months) (range) |
12 (0.7 ~ 612) |
11 (0.7 ~ 120) |
11 (1 ~ 612) |
0.569 |
|
Disease time (months) (range) |
28 (1.6 ~ 279) |
28 (3.5 ~ 156) |
28 (1.6 ~ 279) |
0.878 |
|
No. of infection sites (range) |
3 (1 ~ 8) |
3 (1 ~ 7) |
2 (1 ~ 8) |
0.028 |
| Constitutional symptoms (%) |
138 (70.8%) |
89 (74.8%) |
49 (64.5%) |
0.147 |
| Skin involvement (%) |
71 (36.6%) |
52 (44.1%) |
19 (25.0%) |
0.009 |
| Abscess formation (%) |
44 (22.6%) |
29 (24.4%) |
15 (19.7%) |
0.487 |
| Bone infection (%) |
90 (46.4%) |
59 (50.0%) |
31 (40.8%) |
0.239 |
| Lung infection (%) |
131 (67.5%) |
75 (63.6%) |
56 (73.7%) |
0.159 |
| Lymphadenopathy (%) |
145 (74.4%) |
94 (79.0%) |
51 (67.1%) |
0.067 |
| Bloodstream infection (%) |
43 (22.2%) |
27 (22.9%) |
16 (21.1%) |
0.860 |
| Bone marrow infection (%) |
20 (10.3%) |
15 (12.7%) |
5 (6.6%) |
0.228 |
| No. of species (range) |
2 (1 ~ 6) |
1 (1 ~ 6) |
2 (1 ~ 5) |
0.032 |
| NTM infection (%) |
151 (77.4%) |
107 (89.9%) |
44 (57.9%) |
< 0.001 |
| TM infection (%) |
58 (29.7%) |
21 (17.6%) |
37 (48.7%) |
< 0.001 |
| No. of episodes (range) |
2 (1 ~ 9) |
1 (1 ~ 8) |
2 (1 ~ 9) |
< 0.001 |
| Recurrent infections (%) |
79 (56.0%) |
37 (43.5%) |
42 (75.0%) |
< 0.001 |
| No. of Abx usage (range) |
4 (1 ~ 18) |
4 (1 ~ 12) |
4 (1 ~ 18) |
0.480 |
|
Total treatment time (months) (range) |
17 (0.5 ~ 156) |
18 (0.67 ~ 156) |
11.15 (0.5 ~ 67) |
0.185 |
| Follow-up time (months) (range) |
16 (0.3 ~ 96) |
16.5 (0.3 ~ 96) |
15.5 (0.6 ~ 72) |
0.984 |
| RTX treatment (%)* |
38 (19.5%) |
29 (24.4%) |
5 (6.6%) |
0.002 |
| CTX treatment (%)& |
21 (10.8%) |
15 (12.6%) |
5 (6.7%) |
0.230 |
No. of pathogen: total number of infection pathogens during disease course. NTM, nontubercular mycobacterium; TM, Talaromyces marneffei; No. of episode: number of infection episodes during disease course. No. of Abx usage: the total number of antibiotic used during disease course. RTX, rituximab; CTX, cyclophosphamide. *3 patients received RTX but did not report its effect and 1 patient received RTX before the diagnosis of the disease; these four patients were therefore excluded in outcome study. &1 patient received CTX before the diagnosis of the disease and was excluded in outcome study